The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …

In spite of advances in neuroimaging and other brain biomarkers to assess preclinical
Alzheimer's disease (AD), cognitive assessment has relied on traditional memory paradigms …

Preclinical changes that precede the onset of symptoms and eventual diagnosis of
Alzheimer's disease (AD) are a target for potential preventive interventions. A large body of …

Introduction Total tau (t-tau) and phosphorylated tau (p-tau) are abnormally elevated in the
brain and cerebrospinal fluid of individuals with Alzheimer's disease (AD). Tau is also …

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …

Mild traumatic brain injury (mTBI) leads to diverse symptoms including mood disorders,
cognitive decline, and behavioral changes. In some individuals, these symptoms become …

Abstract Introduction The National Institutes of Health (NIH) Toolbox Cognition Battery
(NIHTB‐CB) was developed to be a common assessment metric across a broad array of …

Introduction The contribution of genetic and environmental factors to the relation between
cerebrospinal fluid (CSF) biomarkers and cognitive decline in preclinical Alzheimer's …

Background: Alzheimer's disease (AD) biomarkers are emerging as critically important for
disease detection and monitoring. Most biomarkers are obtained through invasive, resource …

Abstract Background Rosemary (Rosmarinus officinalis) contains active substances that
have desirable properties for industrial and herbal medicine applications, eg, essential oils …